FDA Drug Shortages

THIS PAGE IS TEMPORARILY UNDER CONSTRUCTION WHILE ENHANCEMENTS ARE UNDERWAY. Drug shortage data continues to be updated while under construction.

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Lorazepam Injection
Status: Currently in Shortage
»Date first posted: 05/03/2018
»Therapeutic Categories: Neurology

Expand all

Akorn Pharmaceuticals (Revised 03/01/2023)

Company Contact Information:
800-932-5676

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Lorazepam, Injection, 2 mg/1 mL (NDC 17478-040-01)	Not available	No new manufacturing of product

Amphastar Pharmaceuticals, Inc. (Revised 09/07/2023)

Company Contact Information:
800-423-4136

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)	Available

Hikma Pharmaceuticals USA, Inc. (formerly West-Ward) (Revised 05/16/2023)

Company Contact Information:
800-631-2174

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 2 mg/1 mL (NDC 0641-6044-25)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 2 mg/1 mL (NDC 0641-6046-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 4 mg/1 mL (NDC 0641-6045-25)	This presentation is temporarily on backorder.	Additional lots are scheduled for manufacturing and will be available in the May 2023 timeframe. Product will be made available as it is released.	Demand increase for the drug
Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)	Inventory is currently available.	Additional lots are scheduled to be manufactured. Product will be made available as it is released.	Demand increase for the drug

Hospira, Inc. (Reverified 09/11/2023)

Company Contact Information:
844-646-4398

Presentation	Availability and Estimated Shortage Duration	Related Information	Shortage Reason (per FDASIA)
Lorazepam, Injection, 2 mg/1 mL (NDC 0409-1985-30)	Available		Demand increase for the drug
Lorazepam, Injection, 2 mg/1 mL (NDC 0409-6778-02)	Discontinued		Discontinuation of the manufacture of the drug